Patents by Inventor József GULYAS

József GULYAS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160375102
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to b e identified receptor.
    Type: Application
    Filed: July 8, 2016
    Publication date: December 29, 2016
    Applicant: Research Development Foundation
    Inventors: Wylie W. VALE, JR., Kathy A. LEWIS, Marilyn H. PERRIN, Koichi KUNITAKE, Jean E. F. RIVIER, Jozsef GULYAS
  • Patent number: 9388229
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: July 12, 2016
    Assignee: Research Development Foundation
    Inventors: Wylie W. Vale, Jr., Kathy A. Lewis, Marilyn H. Perrin, Koichi Kunitake, Jean E. F. Rivier, Jozsef Gulyas
  • Publication number: 20160025197
    Abstract: The invention is a movement transformation device, mechanism and driving gear that consists of a rotation part, a tool that works with a two-way straight line alternating movement, power transmission parts and units that make sure that the power transmission parts stay in position. The inescapable path that has double control and can be established optionally is a form together with the power transmission units in it that are also responsible for direction. The device can be connected to a rotor by an axis-like tool. The rotation of the tool making alternating movement, its rotation movement there and back and its lubrication can be executed upon demand. When the friction factor is smaller, a fixed sliding bush may be satisfactory, in which the two-way movement takes place. Under greater stress balls may be inserted into the fixed sliding bush in order to minimize friction factors. The invention may be used with any machine, equipment, tool or area, where forms of motion need transformation.
    Type: Application
    Filed: December 21, 2012
    Publication date: January 28, 2016
    Inventor: József GULYAS
  • Publication number: 20140288161
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Application
    Filed: February 12, 2014
    Publication date: September 25, 2014
    Applicant: RESEARCH DEVELOPMENT FOUNDATION
    Inventors: Wylie W. VALE, JR., Kathy A. LEWIS, Marilyn H. PERRIN, Koichi KUNITAKE, Jean E. F. RIVIER, Jozsef GULYAS
  • Patent number: 8669092
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: March 11, 2014
    Assignee: Rsearch Development Foundation
    Inventors: Wylie W. Vale, Jr., Kathy A. Lewis, Marilyn H. Perrin, Koichi Kunitake, Jean E. F. Rivier, Jozsef Gulyas
  • Publication number: 20140004603
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Application
    Filed: May 1, 2013
    Publication date: January 2, 2014
    Applicant: Research Development Foundation
    Inventors: Wylie W. VALE, JR., Kathy A. LEWIS, Marilyn H. PERRIN, Koichi KUNITAKE, Jean E. F. RIVIER, Jozsef GULYAS
  • Patent number: 8445425
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: May 21, 2013
    Assignee: Research Development Foundation
    Inventors: Wylie W. Vale, Jr., Kathy A. Lewis, Marilyn H. Perrin, Koichi S. Kunitake, Jean E. Rivier, Jozsef Gulyas
  • Publication number: 20120270792
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Application
    Filed: December 16, 2011
    Publication date: October 25, 2012
    Inventors: Wylie W. Vale, JR., Kathy A. Lewis, Marilyn H. Perrin, Koichi S. Kunitake, Jean E. Rivier, Jozsef Gulyas
  • Patent number: 8084413
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: December 27, 2011
    Assignee: Research Development Foundation
    Inventors: Wylie W. Vale, Jr., Kathy A. Lewis, Marilyn H. Perrin, Koichi S. Kunitake, Jean E. Rivier, Jozsef Gulyas
  • Patent number: 7851588
    Abstract: CRF peptide analogs that bind to CRFR1 with an affinity far greater than they bind to CRFR2. Some of these analogs exhibit CRF agonist activity. One exemplary analog that may be made by solid-phase synthesis is: (cyclo 31-34)[Ac-Pro4,D-Phe12,Nle18,21,Glu31,Lys34]-sucker urotensin(4-41).
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: December 14, 2010
    Assignee: The Salk Institute for Biological Studies
    Inventors: Jean E. F. Rivier, Wylie W. Vale, Jr., Marilyn H. Perrin, Jozsef Gulyas
  • Publication number: 20090156493
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Application
    Filed: November 6, 2008
    Publication date: June 18, 2009
    Inventors: Wylie W. Vale, JR., Kathy A. Lewis, Marilyn H. Perrin, Koichi S. Kunitake, Jean E. Rivier, Jozsef Gulyas
  • Publication number: 20090149629
    Abstract: CRF peptide analogs that bind to CRFR1 with an affinity far greater than they bind to CRFR2. Some of these analogs exhibit CRF agonist activity. One exemplary analog that may be made by solid-phase synthesis is: (cyclo 31-34)[Ac-Pro4, D-Phe12, Nle18,21, Glu31, Lys34]-sucker urotensin(4-41).
    Type: Application
    Filed: February 6, 2009
    Publication date: June 11, 2009
    Applicant: The Salk Institute for Biological Studies
    Inventors: Jean E.F. Rivier, Wylie W. Vale, JR., Marilyn H. Perrin, Jozsef Gulyas
  • Patent number: 7498300
    Abstract: CRF peptide analogs that bind to CRFR1 with an affinity far greater than they bind to CRFR2. These analogs exhibit CRF agonist activity. One exemplary analog that may be made by solid-phase synthesis is (cyclo 31-34)[Ac-Pro4, D-Phe12, Nle21,38, Glu31, Lys34]-r/hCRF(4-41).
    Type: Grant
    Filed: January 22, 2004
    Date of Patent: March 3, 2009
    Assignee: The Salk Institute for Biological Studies
    Inventors: Jean E. F. Rivier, Wyle W. Vale, Jr., Marilyn H. Perrin, Jozsef Gulyas
  • Patent number: 7459427
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Grant
    Filed: August 29, 2005
    Date of Patent: December 2, 2008
    Assignee: Research Development Foundation
    Inventors: Wylie W. Vale, Jr., Kathy A. Lewis, Marilyn H. Perrin, Koichi S. Kunitake, Jean E. Rivier, Jozsef Gulyas
  • Patent number: 7141546
    Abstract: CRF peptide analogs that bind to CRFR2 with an affinity far greater than they bind to CRFR1. These analogs exhibit CRF antagonist activity, and they can be based upon the native structures of sauvagine, CRF, and urocortin.
    Type: Grant
    Filed: July 31, 2002
    Date of Patent: November 28, 2006
    Assignee: The Salk Institute for Biologicial Studies
    Inventors: Jean E. F. Rivier, Wylie W. Vale, Marilyn H. Perrin, Jozsef Gulyas, Dean A. Kirby
  • Publication number: 20060003937
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Application
    Filed: August 29, 2005
    Publication date: January 5, 2006
    Inventors: Wylie Vale, Kathy Lewis, Marilyn Perrin, Koichi Kunitake, Jean Rivier, Jozsef Gulyas
  • Patent number: 6953838
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Grant
    Filed: February 3, 2004
    Date of Patent: October 11, 2005
    Assignee: Research Development Foundation
    Inventors: Wylie W. Vale, Jr., Jean E. Rivier, Koichi S. Kunitake, Kathy A. Lewis, Marilyn H. Perrin, Jozsef Gulyas
  • Patent number: 6812210
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2&agr; or &bgr;. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: November 2, 2004
    Assignee: Research Development Foundation
    Inventors: Wylie W. Vale, Jr., Jean E. River, Koichi S. Kunitake, Kathy A. Lewis, Marilyn H. Perrin, Jozsef Gulyas
  • Publication number: 20040204564
    Abstract: CRF peptide analogs that bind to CRFR1 with an affinity far greater than they bind to CRFR2. These analogs exhibit CRF agonist activity.
    Type: Application
    Filed: January 22, 2004
    Publication date: October 14, 2004
    Inventors: Jean E.F. Rivier, Wylie W. Vale, Marilyn H. Perrin, Jozsef Gulyas
  • Publication number: 20040143095
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2&agr; or &bgr;. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.
    Type: Application
    Filed: February 3, 2004
    Publication date: July 22, 2004
    Applicant: Research Development Foundation
    Inventors: Wylie W. Vale, Jean E. Rivier, Koichi S. Kunitake, Kathy A. Lewis, Marilyn H. Perrin, Jozsef Gulyas